Standardization of the Modified Rodnan Skin Score for Use in Clinical Trials of Systemic Sclerosis
Countries where authors are citing Standardization of the Modified Rodnan Skin Score for Use in Clinical Trials of Systemic Sclerosis
This map shows the geographic impact of Standardization of the Modified Rodnan Skin Score for Use in Clinical Trials of Systemic Sclerosis. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Standardization of the Modified Rodnan Skin Score for Use in Clinical Trials of Systemic Sclerosis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Standardization of the Modified Rodnan Skin Score for Use in Clinical Trials of Systemic Sclerosis more than expected).
Fields of papers citing Standardization of the Modified Rodnan Skin Score for Use in Clinical Trials of Systemic Sclerosis
This network shows the impact of Standardization of the Modified Rodnan Skin Score for Use in Clinical Trials of Systemic Sclerosis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the Standardization of the Modified Rodnan Skin Score for Use in Clinical Trials of Systemic Sclerosis.
About Standardization of the Modified Rodnan Skin Score for Use in Clinical Trials of Systemic Sclerosis
This paper, published in 2017, received 320 indexed citations . Written by Dinesh Khanna, Daniel E. Furst, Philip J. Clements, Yannick Allanore, Murray Baron, L. Czirják, Oliver Distler, Ivan Foeldvari, Masataka Kuwana and Marco Matucci‐Cerinic covering the research area of Pathology and Forensic Medicine, Immunology and Dermatology. It is primarily cited by scholars working on Pathology and Forensic Medicine (290 citations), Dermatology (149 citations) and Pulmonary and Respiratory Medicine (84 citations). Published in Journal of Scleroderma and Related Disorders.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
This paper is also available at doi.org/10.5301/jsrd.5000231.